Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


By impounding iron, FHC foils cell suicide, fuels inflammation


A research team based at the University of Chicago may have found a way to manipulate cell suicide, also known as programmed cell death, a normal process that regulates cell number but that goes awry in chronic inflammatory disorders, cancer and other diseases.

In the 12 Nov. 2004 issue of the journal Cell, the scientists show that a key step in the process of preventing cell suicide is the induction of ferritin heavy chain (FHC), a protein that collects and hoards iron. By sequestering iron -- which cells with suicidal tendencies need to make the harmful substances that induce death -- FHC prevents cellular suicide.

This finding suggests that drugs that modulate FHC or iron metabolism could provide a new and effective approach to anti-inflammatory therapy without the side effects, such as weakening the immune system, that come with current treatments. "In a long and complicated biochemical chain, this is one of the final links, which is exactly what we want," said study author Guido Franzoso, M.D., Ph.D., associate professor in the Ben May Institute for Cancer Research at the University of Chicago. "If we tamper with the front end, it changes everything, but boosting or blocking a downstream component allows us to select for a specific response."

Programmed cell death, also known as apoptosis, is the mechanism all multi-cellular organisms use to eliminate excess or damaged cells. Each year, through a balance of cell death and cell division, humans lose and regain a mass of cells roughly equal to their weight.

When a virus attacks an organism, for example, infected cells commit suicide to protect their healthy neighbors. At the same time, white blood cells multiply rapidly to battle the invader. Once the virus is eliminated, however, most of those virus-chasing white blood cells orchestrate their own demise. If they fail to thin their ranks sufficiently, they keep accumulating, infection after infection, which can lead to autoimmune diseases, such as arthritis, in which left-over warrior cells that no longer have an enemy turn on the self.

The researchers focused on NF-kB, a family of transcription factors -- proteins that turn on or off specific genes. The NF-kB family plays a crucial role in regulating immune and inflammatory responses to microbial invasion. During the early stages of an infection, for instance, NF-kB prevents white blood cells from dying off, allowing them to multiply quickly to fight off infection.

The problem of chronic inflammation begins when these lymphocytes evade cell death after winning the battle. In diseases like Crohn’s or arthritis they can turn their weaponry on healthy cells, which they misidentify as invaders, causing lasting disease and tissue damage. A similar process, when dysfunctional cells fail to die, plays a key role in the accumulation of cancerous cells and then protects those cells from radiation and chemotherapies designed to provoke tumor cell suicide.

Drugs that inhibit NF-kB are already in use for inflammatory bowel disease and certain cancers, such as Hodgkin’s lymphoma and multiple myeloma. But the tasks controlled by NF-kB are so wide ranging that blocking them globally can have serious side effects, such as reduced ability to fight off an infection.

"The goal has been to find new compounds that disrupt unwanted cell survival, but that act downstream from NF-kB so that they won’t harm the immune system," Franzoso said. For a long time that concept was a fantasy, he added, but "as we learn more about this pathway, it has become realistic." NF-kB acts through one subset of genes to influence immunity and a different subset to cause programmed cell death.

To map out those genes, Franzoso and colleagues used a "death-trap" screen. They exposed cells to TNF-Ą, a biochemical signal that can trigger cell death, then collected DNA from cells that survived. Several rounds of this process produced a library of potential protective genes. Next, they used microarrays to detect the genes that were boosted most though this selective process. "This system told us which genes were most enriched by selection," Franzoso said, which provided "a semiquantitative indication of protective efficacy." When they looked closer at each gene associated with survival after exposure to TNF-Ą, they found that FHC was the "pivotal mediator" preventing cell death.

Next, they tracked down the mechanism FHC uses to block apoptosis. They found that by hiding iron, FHC prevented the accumulation of oxygen radicals ¡V extremely unstable molecules that can damage other molecules and cell structures. Without an accumulation of oxygen radicals, cells are unable to take the final steps toward programmed cell death.

"The data indicate that the antioxidant activity of FHC involves iron sequestration and that this sequestration is crucial for suppression of death of white blood cells induced by proinflammatory factors," the authors note. These findings identify FHC as the mechanism "by which NF-kB controls the cascade of intracellular events that ultimately lead to cell suicide."

The next step is to develop drugs that can reduce or raise FHC levels. Lower levels could prevent inflammation and may also enhance the effects of anti-cancer therapies. Higher levels may prevent the unwanted cell death that occurs in neuro-degenerative disorders such as Parkinson’s and Alzheimer’s disease. "Not all that long ago, the NF-kB family, despite it crucial role in so many processes, was a complete puzzle," said Franzoso. "Now we have most of the pieces in place; we know how they fit together. The goal is to use this knowledge to make better therapies."

John Easton | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>